2025年我国有76个创新药获批上市

Core Insights - The National Medical Products Administration of China reported that 76 innovative drugs were approved for market in 2025, surpassing the 48 approved in 2024, marking a historical high [1] - The total value of licensing transactions for innovative drugs in 2025 exceeded $130 billion, with over 150 transactions, also a historical high [1] Group 1: Drug Approvals - In 2025, 76 innovative drugs were approved, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 are domestic innovations, and 9 are imported, with domestic drugs accounting for 80.85% [1] - Of the 23 biological products, 21 are domestic innovations and 2 are imported, with domestic products making up 91.30% [1] Group 2: Industry Position - The approval of these innovative drugs signifies a transition for China's biopharmaceutical sector from a follower to a competitor, with some areas leading globally [1] - This development indicates that China has become a significant player in the global biopharmaceutical innovation landscape [1]